![Maria Grunwald](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Maria Grunwald
Geen lopende functies
Loopbaan van Maria Grunwald
Eerdere bekende functies van Maria Grunwald
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
DYAX CORP. | Corporate Officer/Principal | - | - |
RADIUS HEALTH, INC. | Consultant / Adviseur | - | - |
Office of Technology Development
![]() Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Verkoop & Marketing | 01-01-2012 | - |
Opleiding van Maria Grunwald
The Johns Hopkins University | Doctorate Degree |
Massachusetts Institute of Technology | Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 6 |
Operationeel
Sales & Marketing | 1 |
Corporate Officer/Principal | 1 |
Consultant / Advisor | 1 |
Sectoraal
Finance | 3 |
Health Technology | 3 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Office of Technology Development
![]() Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Dyax Corp.
![]() Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Radius Health, Inc.
![]() Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
- Beurs
- Insiders
- Maria Grunwald
- Ervaring